Efficacy of Everolimus and Tolerability with Long-Term Use
#568
Introduction: Predictors of response to Everolimus in neuroendocrine tumors and long-term safety data are lacking.
Aim(s): To assess disease control rate (DCR) and progression-free survival (PFS) with respect to the number of prior treatment lines and evaluation of frequency and timeframe of pneumonitis.
Materials and methods: We analyzed 60 patients (pts) treated with Everolimus +/- Octreotide LAR 30 mg. Median follow-up was 15 months. Location of primary tumor (PT) was in the pancreas or ileum in 24 cases each (41%), respectively, followed by lung (9%, n=5) and others (CUP, rectum, stomach).
Conference: 9th Annual ENETSConcerence (2012)
Presenting Author:
Authors: Heetfeld M, Tischer E, Denecke T, Perez Fernandez C, Wiedenmann B,
Keywords: everolimus, prior therapies, pneumonitis ,
To read the full abstract, please log into your ENETS Member account.